Stereotactic body radiation therapy in lymph nodal oligometastatic disease

Phase 2

Recruiting

• Conditions: Neoplasms,

• Registration Number: CTRI/2023/02/049773
• Lead Sponsor: PGIMER CHANDIGARH

Brief Summary

| |

| --- |

|The present study aims to assess the feasibility and efficacy of stereotactic body radiation therapy in lymph nodal oligometastasis from various cancers. Local control, toxicity and quality of life will be assessed to determine the impact of treatment on the patient.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-27
• Last Update Posted: 2024-05-04

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Lymph node oligometastatic disease in the neck, mediastinum, retroperitoneum, or pelvis 2) All primary tumors of colorectal, gastric, esophagus, lung, breast, gynaecological cancers or any other site 3) KPS ≥ 70 4) Age > 18 years.

Exclusion Criteria

More than 5 metastases 2) KPS ≤ 60 3) Pre-existing collagen vascular disease 4) Age < 18 years 5) Pregnant and Lactating women 6) Disseminated disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) To assess Overall survival	6 months, 1 year
2) To assess Progression Free Survival	6 months, 1 year

Secondary Outcome Measures

Name	Time	Method
1)To evaluate adverse events according CTCAE	2)To evaluate chemotherapy-free survival

Trial Locations

Locations (1)

PGIMER; 🇮🇳 Chandigarh, CHANDIGARH, India

PGIMER

🇮🇳Chandigarh, CHANDIGARH, India

Divya Khosla

Principal investigator

09876638478

dr_divya_khosla@yahoo.com